15 April 2016

Holding(s) in Company

 

Read more

21 March 2016

Verona Pharma: 2015 in review

VERONA PHARMA PLC - Verona Pharma: 2015 in review

Read more

15 March 2016

Positive results from RPL554 dose-finding study

VERONA PHARMA PLC - Positive results from RPL554 dose-finding study

Read more

15 March 2016

Verona Pharma reports positive results from RPL554 dose-finding study

Read more

10 February 2016

Grant of Share Options

VERONA PHARMA PLC - Grant of Share Options

Read more

21 January 2016

Director Dealing

Verona Pharma plc

Read more

11 January 2016

Directorate Change

VERONA PHARMA PLC - Directorate Change

Read more

3 December 2015

Director Dealing

VERONA PHARMA PLC - Director Dealing

Read more

1 December 2015

Holding(s) in Company

 

Read more

11 November 2015

RPL554 paper published in American Journal of Physiology

VERONA PHARMA PLC - RPL554 paper published in American Journal of Physiology

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us